http://www.thebermudaproject.com
El Paso (2002)1 1231 244 428 52 192 369.23
AES (2002) 909 195 15 2 193 9650.00
Morgan Stanley (2003)2 625 99 138 2 97 4850.00
Citigroup (2003)3 1736 92 349 19 73 384.21
Aon (2002) 1497 87 892 43 44 102.33
Marsh & McLennan (2002) 998 67 417 24 43 179.17
Mirant (2002) 330 65 N/A for Southern (the former parent company)
Halliburton (2002) 618 58 77 8 50 625.00
Bank of America Corp. (2003)4 780 52 544 N/A
Marriott International (2003)5 522 41 313 16 25 156.25
BellSouth (2003) 330 39 563 N/A
Boeing (2003) 284 31 87 10 21 210.00
Williams (2002) 349 31 176 13 18 138.46
Pfizer (2002) 404 30 187 9 21 233.33
PepsiCo (2003)6 550 29 194 14 15 107.14
Viacom (2002) 960 27 576 27 0 0.00
Interpublic Group (2002) 1405 27 431 5 22 440.00
J.P. Morgan Chase (2003)7 284 27 132 11 16 145.45
Fluor (2002) 427 27 N/A N/A
Sara Lee (2002) 525 26 453 14 12 85.71
American Express (2002) 297 25 254 26 -1 -3.85
Lehman Brothers Holdings (2003) 112 23 196 1 22 2200.00
Xerox (2002) 301 23 91 6 17 283.33
Prudential Financial (2003) 382 21 N/A N/A
.......
PFIZER NARROWS DRUG REVIEW TO SEVEN SHOPS
Agencies Competing for Zyrtec, Zoloft and Bextra Assignments
May 09, 2003
QwikFIND ID: AAO66Q
By Rich Thomaselli
NEW YORK (AdAge.com) -- Pfizer Inc. has trimmed its review for direct-to-consumer prescription medications Zyrtec, Zoloft and Bextra to seven finalists, the drug maker said.
Of the seven shops, four are New York-based roster agencies: Interpublic Group of Cos.' McCann-Erickson Worldwide; Publicis Groupe's Publicis; and Omnicom Group's TBWA/Chiat/Day and MNH Healthworks. The three new shops vying for Pfizer business are WPP Group's Berlin Cameron/Red Cell and Publicis' Kaplan Thaler Group, both New York, and Havas' Arnold Worldwide, Boston.
Pitching by brand
By brand, the finalists are broken Related Stories:
CARAT GETS PHARMACIA MEDIA ACCOUNT
Billings Estimated at $147 Million
PFIZER INVITES FIVE NON-ROSTER SHOPS FOR REVIEW
Agencies to Pitch This Week for Top Drug Accounts
down as follows: Kaplan Thaler, MNH, Berlin Cameron and TBWA will compete for the $74 million anti-allergy drug Zyrtec.
For Zoloft, an anti-depressant that had $51 million in ad spending last year, the finalists are Arnold, Kaplan Thaler, MNH and Publicis.
Bextra, the successor drug to the arthritis medication Celebrex, had ad spending of less than $1 million last year, but a Pfizer executive said that is expected to be boosted this year. The finalists for Bextra are Arnold, McCann-Erickson, Publicis, Berlin Cameron and TBWA/Chiat/Day.
Split with Deutsch
Final pitches will be conducted over the rest of the month, with Pfizer looking to make a decision sometime in June. The lucrative DTC accounts became available earlier this year when Pfizer dropped Interpublic's Deutsch, New York, which handled all three. Pfizer and Deutsch parted ways in February after failing to agree on a new contract.
